Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board strengthening the company’s leadership team in preparation for scaling commercial operations internationally

Cambridge, UK 21 July 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – is delighted to announce the appointment of Rob Nixon to its management team as Head of Commercial and Dr Cassie Doherty, Investment Director at Parkwalk, to its board. With years of [...]

By |2020-08-25T08:30:18+00:00July 21st, 2020|news, press release|Comments Off on Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board strengthening the company’s leadership team in preparation for scaling commercial operations internationally

Qkine secures £1.5M series A funding from leading life science investors to accelerate global scale-up and make key hires to leadership team

Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round to accelerate the global scale-up of its commercial operations and make key hires to its leadership team. The funding [...]

By |2020-08-25T08:53:05+00:00June 8th, 2020|news, press release|Comments Off on Qkine secures £1.5M series A funding from leading life science investors to accelerate global scale-up and make key hires to leadership team

Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications, has closed a further round of investment. The £550K funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018. Joining the original investors [...]

By |2020-08-25T09:06:13+00:00June 3rd, 2019|news, press release|Comments Off on Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

So what does the “i” in iteams mean?

Running for over a decade, the iteams programme partners multi-disciplinary teams of PhD students and postdocs with inventors from the University of Cambridge.  As we are a recent spin-out from the academic laboratory of our scientific founder Marko Hyvonen, we have had the pleasure of working with an iteam over the last months. The [...]

By |2020-08-25T09:22:33+00:00June 6th, 2018|news|Comments Off on So what does the “i” in iteams mean?

Building next generation growth factors for organoid-driven precision medicine: a protein engineering project co-funded by Innovate UK

We were delighted to be awarded Innovate UK funding to address issues of quality and availability of growth factors for use in organoid technologies. The Qkine R&D team are applying a combination of protein expression, refolding optimisation and structure-guided protein engineering to improve the biological properties and quality of proteins such as R-spondins, TGFβ1, members of the BMP and FGF family proteins.

By |2020-08-25T09:50:27+00:00May 8th, 2018|news, organoids, protein engineering|Comments Off on Building next generation growth factors for organoid-driven precision medicine: a protein engineering project co-funded by Innovate UK

Qkine backed by Cambridge Enterprise and a quintet of angels

University of Cambridge spin-out Qkine has closed its seed investment round supported by Cambridge Enterprise, the commercialisation arm of the University, and a team of five angels led by Jim Warwick. The amount is undisclosed. Qkine is a specialist manufacturer of proteins that are used for control of stem cell growth and differentiation. The [...]

By |2020-08-25T10:00:53+00:00April 23rd, 2018|news, press release|Comments Off on Qkine backed by Cambridge Enterprise and a quintet of angels

Cambridge Enterprise and Qkine Ltd sign deal to drive stem cell and regenerative medicine research

Cambridge Enterprise and specialist growth factor manufacturer Qkine Ltd sign key licensing deal for Activin A production technology

By |2020-08-25T10:10:05+00:00August 1st, 2017|news|Comments Off on Cambridge Enterprise and Qkine Ltd sign deal to drive stem cell and regenerative medicine research

Go to Top